Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CETIRIZINE, IORATADINE, OR PLACEBO IN SUBJECTS WITH SEASONAL ALLERGICRHINITIS - EFFECTS AFTER CONTROLLED RAGWEED POLLEN CHALLENGE IN AN ENVIRONMENTAL EXPOSURE UNIT
Autore:
DAY JH; BRISCOE M; WIDLITZ MD;
Indirizzi:
QUEENS UNIV,DEPT MED,DIV ALLERGY & IMMUNOL,76 STUART ST KINGSTON ON K7L 2V7 CANADA PFIZER INC,US PHARMACEUT GRP NEW YORK NY 00000
Titolo Testata:
Journal of allergy and clinical immunology
fascicolo: 5, volume: 101, anno: 1998,
pagine: 638 - 645
SICI:
0091-6749(1998)101:5<638:CIOPIS>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; HAY-FEVER; EFFICACY; TERFENADINE; ASTEMIZOLE; MULTICENTER; THERAPY; SAFETY; ANTIHISTAMINE; LORATADINE;
Keywords:
ALLERGIC RHINITIS; CETIRIZINE; ENVIRONMENTAL EXPOSURE UNIT; LORATADINE; PLACEBO; POLLEN CHALLENGE; SEASONAL ALLERGIC RHINITIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
42
Recensione:
Indirizzi per estratti:
Citazione:
J.H. Day et al., "CETIRIZINE, IORATADINE, OR PLACEBO IN SUBJECTS WITH SEASONAL ALLERGICRHINITIS - EFFECTS AFTER CONTROLLED RAGWEED POLLEN CHALLENGE IN AN ENVIRONMENTAL EXPOSURE UNIT", Journal of allergy and clinical immunology, 101(5), 1998, pp. 638-645

Abstract

Background: Allergic rhinitis affects nearly one in 10 Americans. Cetirizine is a newer once-daily selective H-1-antagonist. In traditionalclinical trials, cetirizine has been shown to be safe and effective for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. Objective: To better characterize the efficacy and onset of action of cetirizine in a more controlled but clinically relevant setting, this agent was compared with loratadine and placebo in patients with symptomatic seasonal allergic rhinitis undergoing controlled pollen challenge in an environmental exposure unit (EEU). Methods: This was a double-blind, randomized, parallel-group study. After screening, patients were exposed to rag-weed pollen (primed) in the EEU (up to six exposures), and those with qualifying symptom scores were randomized to controlled pollen exposure (two periods of 5.5 to 6.5hours over 2 days) and once-daily treatment with 10 mg cetirizine (n = 67), 10 mg loratadine (n = 67), or placebo (n = 68). The mean ragweed pollen level was 3480 +/- 350 grains/m(3) (standard deviation). The primary efficacy variables were the total symptom complex (TSC) and the major symptom complex (MSC) scores. Symptoms were evaluated every half hour in the EEU throughout the study. Results: Cetirizine produced a 36.7% mean reduction in TSC scores overall versus 15.4% with loratadine and 12.0% with placebo (p less than or equal to 0.01), Cetirizine also produced a 37.4% mean reduction in MSC scores overall versus 14.7% with loratadine and 6.7% with placebo (p less than or equal to 0.01). Onset of action as assessed by reductions in TSC and MSC scores versus placebo was evident within 1 hour with cetirizine (p less than or equal to 0.02) and 3 hours with loratadine (p less than or equal to 0.03). The incidence of treatment-related side effects was similar among groups, with headache reported most commonly in each group. Conclusion: Cetirizine is well tolerated and effective in reducing symptoms of seasonal allergic rhinitis in patients undergoing controlled pollen challenge.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/06/18 alle ore 00:48:34